KCT0009068已完成Unknown
A 12-Week, Randomized, Parallel, Double-blind, Placebo-controlled clinical study of eggshell membrane powder to assess skin health improvement and safety evaluation
mariedm0 个研究点目标入组 100 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 25(Year) 至 60(Year)（—）
- 性别
- All
入选标准
- •1) Men and women aged 25 to 60 with 3 grade to 7 grade in wrinkles and skin color around the eyes and 49 A.U. or less in the cheek area
- •2) A healthy person with no acute, chronic physical illness, including skin disease
- •3) A person who voluntarily prepared and signed a consent form to participate in the clinical trial after hearing sufficient explanation from the researcher about the purpose, content, possible adverse reactions, etc. of the study
- •4) A person who can follow up during the study period
排除标准
- •1) A person who has a skin disease or has a specific allergic reaction to a raw material similar to a clinical trial product
- •2) A person who has used oral and skin external preparations containing steroids or retinoids within 24 weeks of screening
- •3) A person who participated in a similar clinical trial and the same study within 24 weeks of screening
- •4) A person with skin abnormalities such as spots, acne, erythema, capillary dilatation, etc. on the test site
- •5) A person who has used cosmetics or medicines of the same or similar ingredients on the test site within 12 weeks of screening
- •6) Those who have taken medicines and herbal medicines that can affect test results within 12 weeks of screening (hormone preparations, oral contraceptives, diuretics, acne treatments, hair loss drugs, Allergic rhinitis medications (Fexo-genadine components such as alicresin and allegra) and ACE inhibitor (angiotensin converting enzyme inhibitor) among high blood pressure drugs
- •7) A person who has continuously consumed health functional foods and general foods that may affect the test results within 12 weeks of screening (this test material and
- •Health functional foods or general foods containing similar ingredients, protein-containing foods, collagen-containing products, hyaluronic acid, biotin, beer yeast, skin lactic acid bacteria, aloe gel, konjac potato extract, pomegranate-containing products, Vitamin C, ceramide, gamma-linolenic acid, amphitheater, N-acetylglucosamine, noni fruit, chlorella, Spirulina, etc.)
- •8) A person who has undergone procedures (skin ablation, Botox, laser, other skincare, etc.) on the test site within 24 weeks of screening
- •9) A person who plans to become pregnant, is pregnant, or is breastfeeding within 24 weeks of screening
- •10) Those who have experienced drug-sensitive (hyperactive) or allergic reactions
- •11) People with uncontrolled hypertension or diabetes (excluding those who take drugs with NO synthetic metastasis among high blood pressure drugs)
- •12) Those with clinically significant diseases (cardiovascular, dyslipidemia, endocrine, digestive, urinary diseases, neuropsychiatric diseases, malignancies) that require treatment (however, after the operation
- •Participation is possible if it has not recurred for more than 5 years)
- •13) Those whose diagnostic test results are deemed inappropriate during screening visits (ALT (GOT), those whose AST (GPT) is more than three times the upper limit of the reference range, and those whose serum creatine is 2.0 mg/dl or more)
- •14) A smoker or a person who has quit smoking for less than one year
- •15) Other persons deemed difficult to participate in the examination due to the judgment of the research manager
研究者
相似试验
已完成
Unknown
Clinical study of rose petals extract to improve skin health (maintaining skin health and moisturizing skin from skin damage caused by ultraviolet rays)KCT0009064ovawells100
进行中（未招募）
不适用
A twelve-week, randomized, double-blind, parallel-group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with atenolol in patients with essential hypertension - non aplicableHypertensionEUCTR2004-002252-33-ESovartis Farmacéutica S.A672
进行中（未招募）
不适用
A twelve-week, randomized, double-blind, parallel-group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with atenolol in patients with essential hypertensioHypertensionEUCTR2004-002252-33-DEovartis Pharma Services AG672
尚未招募
不适用
Clinical trial to evaluate the efficacy and safety of Omija on obesityKCT0003951Wonkwang University, Gwangju Medical Center60
进行中（未招募）
不适用
A twelve week, randomized, double-blind, parallel-group multicentre study to evaluate the efficacy and safety of the combination of aliskiren/ramipril/amlodipine (300/10/10mg), compared to the combinations of ramipril/amlodipine (10/10mg) and aliskiren/amlodipine (300/10mg) in patients with essential hypertension and metabolic syndrome not adequately responsive to amlodipine 10mg. - N.A.patients with essential hypertension and metabolic syndrome.EUCTR2007-003677-10-GBovartis Pharmaceuticals UK Ltd